Organization | Presidio Ospedaliero Spedali Civili di Brescia

Presidio Ospedaliero Spedali Civili di Brescia Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial

2011

NCT01681563

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2013

Timeline

NOW

Now

Alternative names

Presidi Ospedalieri Spedali Civili di Brescia | Presidi Ospedalieri Spedali Civili di Brescia Divisione di Ematologia

Active Ingredients

Drugs in Phase 2 Trials (10)

cisplatin (platinol) (2 trials)

cyclophosphamide (cytoxan) (1 trial)

docetaxel (taxotere) (2 trials)

doxorubicin (Doxil) (2 trials)

etoposide (vepesid) (2 trials)

fluorouracil (efudex) (2 trials)

ifosfamide (ifex) (2 trials)

leucovorin (2 trials)

ofatumumab (arzerra) (1 trial)

pentostatin (nipent) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 3
# of Trial APIs: 10